Two quick comments as I have a couple of road trips coming up.
1. Any long term tox data in the 2 animal species could give a hint if any would be available. But the dosings in Ph2 were allowed based on animal tox safety data, in what I should emphasize are normal healthy animals, usually dogs and rats. I am not privy to company tox data. So although any coagulation or fibrinolytic issue is theoretical, it remains possible. There is no way to predict any issue in the longer term readout.
2 As to a counter drug to a theoretical issue, there is insufficient molecular information as to how to any molecular basis/ For that matter, it is not known whether either isoform of the 2 THalpha receptors, or either isoform of the 2 THbeta receptors, are responsible for this theoretical issue.
I would suspect any issue that may arise might be resolved upon cessation of dosing. Certainly if a signal were to appear in animal tox studies, reversibility would have been assessed. And that data would have been seen by the FDA. Note that no signal of tox was seen in the two DSMB committee reads of the NASH data.